Skip to main content

Your Life-Saving Gift Will Be Matched

Found with his flippers tucked tightly against his body, California sea lion Pockets looked like a sick child with a bellyache.

Pockets was battling a potentially fatal bacterial disease, leptospirosis. We've rescued nearly 500 sea lions affected by this year's intense outbreak.

With your matched gift, you’ll not only help provide the meals and advanced medical care needed to help a sea lion like Pockets recover, but also support our researchers in learning more about this disease.

Match my life-saving gift
California sea lion
northern elephant seal Mizuna

Pharmacokinetic Study of Oral Ɛ-Aminocaproic Acid in the Northern Elephant Seal

Pharmacokinetic study of oral Ɛ-Aminocaproic acid in the Northern elephant seal (Mirounga angustirostris)
  • Lungworm
  • Pharmacokinetics

Abstract

ϵ-Aminocaproic acid (EACA) is a lysine analogue antifibrinolytic drug used to treat bleeding disorders in humans and domestic animals. Its use in zoological medicine is rare, and dosage is anecdotal. One possible application of EACA is to treat bleeding associated with prepatent Otostrongylus arteritis in Northern elephant seals (Mirounga angustirostris) presenting to wildlife rehabilitation centers. This study used an in vitro model of hyperfibrinolysis and a thromboelastograph-based assay to estimate the therapeutic plasma concentration of EACA in elephant seals (85 μg/ml, 95% confidence interval = 73.8–96.8 μg/ml). A concurrent pharmacokinetic study of orally administered, single-dose EACA found that doses of 75 and 100 mg/kg achieved therapeutic plasma concentrations (>85 μg/ml), but the drug was rapidly eliminated and remained in the therapeutic range for only 0.4 and 1.5 hr, respectively. Models of repeated oral dosing at 100 mg/kg every 6 hr predict that therapeutic plasma concentration will be maintained for 31.7% (7.6 hr) of a 24-hr period. More frequent dosing would be required to maintain continuous therapeutic concentrations but would be impractical in a wildlife rehabilitation setting. Further pharmacodynamic studies to evaluate the duration of action of EACA in elephant seals and a prospective, placebo-controlled study are needed to determine if EACA is effective in decreasing bleeding associated with prepatent Otostrongylus arteritis and other bleeding disorders in this species. 


Kaye, S., Johnson, S., Arnold, R.D., Nie, B., Davis, J.T., Gulland, F., Abou-Madi, N., Fletcher, D.J. 2016. Pharmacokinetic study of oral Ɛ-Aminocaproic acid in the Northern elephant seal (Mirounga angustirostris). Journal of Zoo and Wildlife Medicine. 47(2): 438-446.

lungworm
pharmacokinetics

Related Publications

Recent News